A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine
Abstract Chronic migraine is a debilitating disorder that affects 2 % of the global population and imparts a significant societal and economic impact. The cornerstones of chronic migraine management include making an accurate diagnosis, patient education, treatment of comorbid conditions, and select...
Ausführliche Beschreibung
Autor*in: |
Starling, Amaal J. [verfasserIn] Vargas, Bert B. [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2015 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
Enthalten in: Current Review of Pain - Current Medicine Group, 1998, 19(2015), 10 vom: 19. Aug. |
---|---|
Übergeordnetes Werk: |
volume:19 ; year:2015 ; number:10 ; day:19 ; month:08 |
Links: |
---|
DOI / URN: |
10.1007/s11916-015-0521-0 |
---|
Katalog-ID: |
SPR023010517 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR023010517 | ||
003 | DE-627 | ||
005 | 20201125053704.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201006s2015 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s11916-015-0521-0 |2 doi | |
035 | |a (DE-627)SPR023010517 | ||
035 | |a (SPR)s11916-015-0521-0-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Starling, Amaal J. |e verfasserin |4 aut | |
245 | 1 | 2 | |a A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine |
264 | 1 | |c 2015 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Chronic migraine is a debilitating disorder that affects 2 % of the global population and imparts a significant societal and economic impact. The cornerstones of chronic migraine management include making an accurate diagnosis, patient education, treatment of comorbid conditions, and selection of an appropriate, evidence-based acute and preventive treatment regimen. Although it is common to treat chronic migraine with preventive medications effective for episodic migraine, a number of treatment options exist with specific evidence for effectiveness in chronic migraine. Currently, onabotulinumtoxinA injections are the only FDA-approved preventive treatment for chronic migraine. A number of non-medication treatment options including occipital nerve and supraorbital nerve stimulation have shown promise as effective prevention for patients either unable to tolerate or unable to obtain relief from oral medications, but more research is necessary. | ||
650 | 4 | |a Chronic migraine |7 (dpeaa)DE-He213 | |
650 | 4 | |a Migraine |7 (dpeaa)DE-He213 | |
650 | 4 | |a Headache |7 (dpeaa)DE-He213 | |
650 | 4 | |a Chronic daily headache |7 (dpeaa)DE-He213 | |
650 | 4 | |a Treatment |7 (dpeaa)DE-He213 | |
700 | 1 | |a Vargas, Bert B. |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current Review of Pain |d Current Medicine Group, 1998 |g 19(2015), 10 vom: 19. Aug. |w (DE-627)SPR023001666 |7 nnns |
773 | 1 | 8 | |g volume:19 |g year:2015 |g number:10 |g day:19 |g month:08 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11916-015-0521-0 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_252 | ||
951 | |a AR | ||
952 | |d 19 |j 2015 |e 10 |b 19 |c 08 |
author_variant |
a j s aj ajs b b v bb bbv |
---|---|
matchkey_str |
starlingamaaljvargasbertb:2015----:nraieeiwfvdneaepeetvotos |
hierarchy_sort_str |
2015 |
publishDate |
2015 |
allfields |
10.1007/s11916-015-0521-0 doi (DE-627)SPR023010517 (SPR)s11916-015-0521-0-e DE-627 ger DE-627 rakwb eng Starling, Amaal J. verfasserin aut A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Chronic migraine is a debilitating disorder that affects 2 % of the global population and imparts a significant societal and economic impact. The cornerstones of chronic migraine management include making an accurate diagnosis, patient education, treatment of comorbid conditions, and selection of an appropriate, evidence-based acute and preventive treatment regimen. Although it is common to treat chronic migraine with preventive medications effective for episodic migraine, a number of treatment options exist with specific evidence for effectiveness in chronic migraine. Currently, onabotulinumtoxinA injections are the only FDA-approved preventive treatment for chronic migraine. A number of non-medication treatment options including occipital nerve and supraorbital nerve stimulation have shown promise as effective prevention for patients either unable to tolerate or unable to obtain relief from oral medications, but more research is necessary. Chronic migraine (dpeaa)DE-He213 Migraine (dpeaa)DE-He213 Headache (dpeaa)DE-He213 Chronic daily headache (dpeaa)DE-He213 Treatment (dpeaa)DE-He213 Vargas, Bert B. verfasserin aut Enthalten in Current Review of Pain Current Medicine Group, 1998 19(2015), 10 vom: 19. Aug. (DE-627)SPR023001666 nnns volume:19 year:2015 number:10 day:19 month:08 https://dx.doi.org/10.1007/s11916-015-0521-0 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_73 GBV_ILN_252 AR 19 2015 10 19 08 |
spelling |
10.1007/s11916-015-0521-0 doi (DE-627)SPR023010517 (SPR)s11916-015-0521-0-e DE-627 ger DE-627 rakwb eng Starling, Amaal J. verfasserin aut A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Chronic migraine is a debilitating disorder that affects 2 % of the global population and imparts a significant societal and economic impact. The cornerstones of chronic migraine management include making an accurate diagnosis, patient education, treatment of comorbid conditions, and selection of an appropriate, evidence-based acute and preventive treatment regimen. Although it is common to treat chronic migraine with preventive medications effective for episodic migraine, a number of treatment options exist with specific evidence for effectiveness in chronic migraine. Currently, onabotulinumtoxinA injections are the only FDA-approved preventive treatment for chronic migraine. A number of non-medication treatment options including occipital nerve and supraorbital nerve stimulation have shown promise as effective prevention for patients either unable to tolerate or unable to obtain relief from oral medications, but more research is necessary. Chronic migraine (dpeaa)DE-He213 Migraine (dpeaa)DE-He213 Headache (dpeaa)DE-He213 Chronic daily headache (dpeaa)DE-He213 Treatment (dpeaa)DE-He213 Vargas, Bert B. verfasserin aut Enthalten in Current Review of Pain Current Medicine Group, 1998 19(2015), 10 vom: 19. Aug. (DE-627)SPR023001666 nnns volume:19 year:2015 number:10 day:19 month:08 https://dx.doi.org/10.1007/s11916-015-0521-0 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_73 GBV_ILN_252 AR 19 2015 10 19 08 |
allfields_unstemmed |
10.1007/s11916-015-0521-0 doi (DE-627)SPR023010517 (SPR)s11916-015-0521-0-e DE-627 ger DE-627 rakwb eng Starling, Amaal J. verfasserin aut A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Chronic migraine is a debilitating disorder that affects 2 % of the global population and imparts a significant societal and economic impact. The cornerstones of chronic migraine management include making an accurate diagnosis, patient education, treatment of comorbid conditions, and selection of an appropriate, evidence-based acute and preventive treatment regimen. Although it is common to treat chronic migraine with preventive medications effective for episodic migraine, a number of treatment options exist with specific evidence for effectiveness in chronic migraine. Currently, onabotulinumtoxinA injections are the only FDA-approved preventive treatment for chronic migraine. A number of non-medication treatment options including occipital nerve and supraorbital nerve stimulation have shown promise as effective prevention for patients either unable to tolerate or unable to obtain relief from oral medications, but more research is necessary. Chronic migraine (dpeaa)DE-He213 Migraine (dpeaa)DE-He213 Headache (dpeaa)DE-He213 Chronic daily headache (dpeaa)DE-He213 Treatment (dpeaa)DE-He213 Vargas, Bert B. verfasserin aut Enthalten in Current Review of Pain Current Medicine Group, 1998 19(2015), 10 vom: 19. Aug. (DE-627)SPR023001666 nnns volume:19 year:2015 number:10 day:19 month:08 https://dx.doi.org/10.1007/s11916-015-0521-0 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_73 GBV_ILN_252 AR 19 2015 10 19 08 |
allfieldsGer |
10.1007/s11916-015-0521-0 doi (DE-627)SPR023010517 (SPR)s11916-015-0521-0-e DE-627 ger DE-627 rakwb eng Starling, Amaal J. verfasserin aut A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Chronic migraine is a debilitating disorder that affects 2 % of the global population and imparts a significant societal and economic impact. The cornerstones of chronic migraine management include making an accurate diagnosis, patient education, treatment of comorbid conditions, and selection of an appropriate, evidence-based acute and preventive treatment regimen. Although it is common to treat chronic migraine with preventive medications effective for episodic migraine, a number of treatment options exist with specific evidence for effectiveness in chronic migraine. Currently, onabotulinumtoxinA injections are the only FDA-approved preventive treatment for chronic migraine. A number of non-medication treatment options including occipital nerve and supraorbital nerve stimulation have shown promise as effective prevention for patients either unable to tolerate or unable to obtain relief from oral medications, but more research is necessary. Chronic migraine (dpeaa)DE-He213 Migraine (dpeaa)DE-He213 Headache (dpeaa)DE-He213 Chronic daily headache (dpeaa)DE-He213 Treatment (dpeaa)DE-He213 Vargas, Bert B. verfasserin aut Enthalten in Current Review of Pain Current Medicine Group, 1998 19(2015), 10 vom: 19. Aug. (DE-627)SPR023001666 nnns volume:19 year:2015 number:10 day:19 month:08 https://dx.doi.org/10.1007/s11916-015-0521-0 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_73 GBV_ILN_252 AR 19 2015 10 19 08 |
allfieldsSound |
10.1007/s11916-015-0521-0 doi (DE-627)SPR023010517 (SPR)s11916-015-0521-0-e DE-627 ger DE-627 rakwb eng Starling, Amaal J. verfasserin aut A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Chronic migraine is a debilitating disorder that affects 2 % of the global population and imparts a significant societal and economic impact. The cornerstones of chronic migraine management include making an accurate diagnosis, patient education, treatment of comorbid conditions, and selection of an appropriate, evidence-based acute and preventive treatment regimen. Although it is common to treat chronic migraine with preventive medications effective for episodic migraine, a number of treatment options exist with specific evidence for effectiveness in chronic migraine. Currently, onabotulinumtoxinA injections are the only FDA-approved preventive treatment for chronic migraine. A number of non-medication treatment options including occipital nerve and supraorbital nerve stimulation have shown promise as effective prevention for patients either unable to tolerate or unable to obtain relief from oral medications, but more research is necessary. Chronic migraine (dpeaa)DE-He213 Migraine (dpeaa)DE-He213 Headache (dpeaa)DE-He213 Chronic daily headache (dpeaa)DE-He213 Treatment (dpeaa)DE-He213 Vargas, Bert B. verfasserin aut Enthalten in Current Review of Pain Current Medicine Group, 1998 19(2015), 10 vom: 19. Aug. (DE-627)SPR023001666 nnns volume:19 year:2015 number:10 day:19 month:08 https://dx.doi.org/10.1007/s11916-015-0521-0 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_73 GBV_ILN_252 AR 19 2015 10 19 08 |
language |
English |
source |
Enthalten in Current Review of Pain 19(2015), 10 vom: 19. Aug. volume:19 year:2015 number:10 day:19 month:08 |
sourceStr |
Enthalten in Current Review of Pain 19(2015), 10 vom: 19. Aug. volume:19 year:2015 number:10 day:19 month:08 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Chronic migraine Migraine Headache Chronic daily headache Treatment |
isfreeaccess_bool |
false |
container_title |
Current Review of Pain |
authorswithroles_txt_mv |
Starling, Amaal J. @@aut@@ Vargas, Bert B. @@aut@@ |
publishDateDaySort_date |
2015-08-19T00:00:00Z |
hierarchy_top_id |
SPR023001666 |
id |
SPR023010517 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR023010517</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20201125053704.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201006s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s11916-015-0521-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR023010517</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s11916-015-0521-0-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Starling, Amaal J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="2"><subfield code="a">A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Chronic migraine is a debilitating disorder that affects 2 % of the global population and imparts a significant societal and economic impact. The cornerstones of chronic migraine management include making an accurate diagnosis, patient education, treatment of comorbid conditions, and selection of an appropriate, evidence-based acute and preventive treatment regimen. Although it is common to treat chronic migraine with preventive medications effective for episodic migraine, a number of treatment options exist with specific evidence for effectiveness in chronic migraine. Currently, onabotulinumtoxinA injections are the only FDA-approved preventive treatment for chronic migraine. A number of non-medication treatment options including occipital nerve and supraorbital nerve stimulation have shown promise as effective prevention for patients either unable to tolerate or unable to obtain relief from oral medications, but more research is necessary.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chronic migraine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Migraine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Headache</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chronic daily headache</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Treatment</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vargas, Bert B.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Current Review of Pain</subfield><subfield code="d">Current Medicine Group, 1998</subfield><subfield code="g">19(2015), 10 vom: 19. Aug.</subfield><subfield code="w">(DE-627)SPR023001666</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:10</subfield><subfield code="g">day:19</subfield><subfield code="g">month:08</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s11916-015-0521-0</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_252</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2015</subfield><subfield code="e">10</subfield><subfield code="b">19</subfield><subfield code="c">08</subfield></datafield></record></collection>
|
author |
Starling, Amaal J. |
spellingShingle |
Starling, Amaal J. misc Chronic migraine misc Migraine misc Headache misc Chronic daily headache misc Treatment A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine |
authorStr |
Starling, Amaal J. |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR023001666 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut |
collection |
springer |
remote_str |
true |
illustrated |
Not Illustrated |
topic_title |
A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine Chronic migraine (dpeaa)DE-He213 Migraine (dpeaa)DE-He213 Headache (dpeaa)DE-He213 Chronic daily headache (dpeaa)DE-He213 Treatment (dpeaa)DE-He213 |
topic |
misc Chronic migraine misc Migraine misc Headache misc Chronic daily headache misc Treatment |
topic_unstemmed |
misc Chronic migraine misc Migraine misc Headache misc Chronic daily headache misc Treatment |
topic_browse |
misc Chronic migraine misc Migraine misc Headache misc Chronic daily headache misc Treatment |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Current Review of Pain |
hierarchy_parent_id |
SPR023001666 |
hierarchy_top_title |
Current Review of Pain |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)SPR023001666 |
title |
A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine |
ctrlnum |
(DE-627)SPR023010517 (SPR)s11916-015-0521-0-e |
title_full |
A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine |
author_sort |
Starling, Amaal J. |
journal |
Current Review of Pain |
journalStr |
Current Review of Pain |
lang_code |
eng |
isOA_bool |
false |
recordtype |
marc |
publishDateSort |
2015 |
contenttype_str_mv |
txt |
author_browse |
Starling, Amaal J. Vargas, Bert B. |
container_volume |
19 |
format_se |
Elektronische Aufsätze |
author-letter |
Starling, Amaal J. |
doi_str_mv |
10.1007/s11916-015-0521-0 |
author2-role |
verfasserin |
title_sort |
narrative review of evidence-based preventive options for chronic migraine |
title_auth |
A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine |
abstract |
Abstract Chronic migraine is a debilitating disorder that affects 2 % of the global population and imparts a significant societal and economic impact. The cornerstones of chronic migraine management include making an accurate diagnosis, patient education, treatment of comorbid conditions, and selection of an appropriate, evidence-based acute and preventive treatment regimen. Although it is common to treat chronic migraine with preventive medications effective for episodic migraine, a number of treatment options exist with specific evidence for effectiveness in chronic migraine. Currently, onabotulinumtoxinA injections are the only FDA-approved preventive treatment for chronic migraine. A number of non-medication treatment options including occipital nerve and supraorbital nerve stimulation have shown promise as effective prevention for patients either unable to tolerate or unable to obtain relief from oral medications, but more research is necessary. |
abstractGer |
Abstract Chronic migraine is a debilitating disorder that affects 2 % of the global population and imparts a significant societal and economic impact. The cornerstones of chronic migraine management include making an accurate diagnosis, patient education, treatment of comorbid conditions, and selection of an appropriate, evidence-based acute and preventive treatment regimen. Although it is common to treat chronic migraine with preventive medications effective for episodic migraine, a number of treatment options exist with specific evidence for effectiveness in chronic migraine. Currently, onabotulinumtoxinA injections are the only FDA-approved preventive treatment for chronic migraine. A number of non-medication treatment options including occipital nerve and supraorbital nerve stimulation have shown promise as effective prevention for patients either unable to tolerate or unable to obtain relief from oral medications, but more research is necessary. |
abstract_unstemmed |
Abstract Chronic migraine is a debilitating disorder that affects 2 % of the global population and imparts a significant societal and economic impact. The cornerstones of chronic migraine management include making an accurate diagnosis, patient education, treatment of comorbid conditions, and selection of an appropriate, evidence-based acute and preventive treatment regimen. Although it is common to treat chronic migraine with preventive medications effective for episodic migraine, a number of treatment options exist with specific evidence for effectiveness in chronic migraine. Currently, onabotulinumtoxinA injections are the only FDA-approved preventive treatment for chronic migraine. A number of non-medication treatment options including occipital nerve and supraorbital nerve stimulation have shown promise as effective prevention for patients either unable to tolerate or unable to obtain relief from oral medications, but more research is necessary. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_73 GBV_ILN_252 |
container_issue |
10 |
title_short |
A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine |
url |
https://dx.doi.org/10.1007/s11916-015-0521-0 |
remote_bool |
true |
author2 |
Vargas, Bert B. |
author2Str |
Vargas, Bert B. |
ppnlink |
SPR023001666 |
mediatype_str_mv |
c |
isOA_txt |
false |
hochschulschrift_bool |
false |
doi_str |
10.1007/s11916-015-0521-0 |
up_date |
2024-07-03T16:17:14.042Z |
_version_ |
1803575292379267072 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR023010517</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20201125053704.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201006s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s11916-015-0521-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR023010517</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s11916-015-0521-0-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Starling, Amaal J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="2"><subfield code="a">A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Chronic migraine is a debilitating disorder that affects 2 % of the global population and imparts a significant societal and economic impact. The cornerstones of chronic migraine management include making an accurate diagnosis, patient education, treatment of comorbid conditions, and selection of an appropriate, evidence-based acute and preventive treatment regimen. Although it is common to treat chronic migraine with preventive medications effective for episodic migraine, a number of treatment options exist with specific evidence for effectiveness in chronic migraine. Currently, onabotulinumtoxinA injections are the only FDA-approved preventive treatment for chronic migraine. A number of non-medication treatment options including occipital nerve and supraorbital nerve stimulation have shown promise as effective prevention for patients either unable to tolerate or unable to obtain relief from oral medications, but more research is necessary.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chronic migraine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Migraine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Headache</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chronic daily headache</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Treatment</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vargas, Bert B.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Current Review of Pain</subfield><subfield code="d">Current Medicine Group, 1998</subfield><subfield code="g">19(2015), 10 vom: 19. Aug.</subfield><subfield code="w">(DE-627)SPR023001666</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:10</subfield><subfield code="g">day:19</subfield><subfield code="g">month:08</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s11916-015-0521-0</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_252</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2015</subfield><subfield code="e">10</subfield><subfield code="b">19</subfield><subfield code="c">08</subfield></datafield></record></collection>
|
score |
7.399768 |